| |
|
|
12 months
to 31 Dec
1998
(restated)
|
|
12 months
to 31 Dec
1999
(restated)
|
|
12 months
to 31 Dec
2000
(restated)
|
|
12 months
to 31 Dec
2001
(restated)
|
|
12 months
to 31 Dec
2002
|
|
| |
£m |
|
£m |
|
£m |
|
£m |
|
£m |
|
|
| Key data |
|
|
|
|
|
|
|
|
|
|
| Sales |
1,388.9 |
|
1,374.6 |
|
1,377.6 |
|
1,602.5 |
|
1,618.2 |
|
| – continuing operations |
1,113.7 |
|
1,271.0 |
|
1,377.6 |
|
1,602.5 |
|
1,618.2 |
|
| – discontinued operations |
275.2 |
|
103.6 |
|
– |
|
– |
|
– |
|
|
| Amersham Health |
161.0 |
|
178.1 |
|
194.6 |
|
240.9 |
|
255.6 |
|
| Amersham Biosciences |
70.5 |
|
81.6 |
|
63.3 |
|
72.4 |
|
75.3 |
|
| Corporate |
(9.9 |
) |
(9.7 |
) |
(16.7 |
) |
(20.8 |
) |
(21.1 |
) |
|
| Operating profit of continuing
operations before exceptional items and goodwill amortisation |
221.6 |
|
250.0 |
|
241.2 |
|
292.5 |
|
309.8 |
|
| Discontinued operations |
37.7 |
|
10.3 |
|
– |
|
– |
|
– |
|
|
| Total operating profit before
exceptional items and goodwill amortisation |
259.3 |
|
260.3 |
|
241.2 |
|
292.5 |
|
309.8 |
|
| Interest |
(33.3 |
) |
(27.1 |
) |
(10.0 |
) |
(8.7 |
) |
(7.1 |
) |
| Amounts written off investments |
– |
|
– |
|
– |
|
(4.4 |
) |
(2.4 |
) |
|
| Profit before tax and before
exceptional items and goodwill amortisation |
226.0 |
|
233.2 |
|
231.2 |
|
279.4 |
|
300.3 |
|
| Exceptional items |
(35.1 |
) |
(55.2 |
) |
(27.0 |
) |
46.6 |
|
– |
|
| Goodwill amortisation |
(2.4 |
) |
(8.9 |
) |
(10.7 |
) |
(11.7 |
) |
(36.6 |
) |
|
| Profit before taxation after
exceptional items and goodwill amortisation |
188.5 |
|
169.1 |
|
193.5 |
|
314.3 |
|
263.7 |
|
|
| Profit attributable to shareholders |
99.4 |
|
87.9 |
|
107.0 |
|
210.7 |
|
178.7 |
|
|
| Employment of
shareholders’ funds |
|
|
|
|
|
|
|
|
|
| Fixed assets |
751.2 |
|
677.5 |
|
776.7 |
|
787.9 |
|
1,491.4 |
|
| Net current assets |
398.4 |
|
360.0 |
|
266.2 |
|
269.8 |
|
146.5 |
|
| Non-current liabilities (incl.deferred
income) |
(671.9 |
) |
(412.9 |
) |
(373.7 |
) |
(158.0 |
) |
(207.5 |
) |
| Provisions |
(213.5 |
) |
(199.3 |
) |
(190.6 |
) |
(240.8 |
) |
(253.5 |
) |
|
| Net assets |
264.2 |
|
425.3 |
|
478.6 |
|
658.9 |
|
1,176.9 |
|
|
| Shareholders’funds |
215.1 |
|
363.7 |
|
416.9 |
|
596.3 |
|
1,172.0 |
|
| Minority interests |
49.1 |
|
61.6 |
|
61.7 |
|
62.6 |
|
4.9 |
|
|
| |
264.2 |
|
425.3 |
|
478.6 |
|
658.9 |
|
1,176.9 |
|
|
| Net debt |
523.8 |
|
298.9 |
|
323.5 |
|
25.4 |
|
182.3 |
|
|
Share statistics |
|
|
|
|
|
|
|
|
|
|
| Earnings per share |
|
|
|
|
|
|
|
|
|
|
| – basic |
15.8p |
|
13.9p |
|
17.0p |
|
33.2p |
|
26.1p |
|
| – before exceptional items
and goodwill amortisation |
19.2p |
|
20.5p |
|
21.9p |
|
26.6p |
|
29.9p |
|
| Dividends per share |
5.30p |
|
5.85p |
|
6.40p |
|
7.10p |
|
7.80p |
|
|
The period ending 31 December 1998 has been restated following
the implementation of FRS 12. Sales have been restated to reclassify
Industrial Quality & Safety Assurance and Nycomed Pharma as discontinued
operations.
Figures for periods ending 31 December 1998, 1999 and 2000 have
been restated following the introduction of FRS18.
Figures for periods ending 31 December 1998, 1999, 2000 and 2001
have been restated following the introduction of FRS19, as explained
in note 36 (PDF)
to the financial statements.
|
|
|
|
|
